Advertisement

Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: A review

Published:October 03, 2020DOI:https://doi.org/10.1016/j.hrthm.2020.09.018
      Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy, with a prevalence of 23% and incidence of 3.1%. The risk of thromboembolism is high in patients with hypertrophic cardiomyopathy regardless of CHADS2-VASc score. This review includes 5 observational studies that focused on prevention of thromboembolism in patients with hypertrophic cardiomyopathy and atrial fibrillation. The studies evaluated and compared outcomes between patients receiving either warfarin or direct oral anticoagulants. Data showed that direct oral anticoagulants are effective and safe in this patient population and may have a benefit over warfarin for thromboprophylaxis in patients with hypertrophic cardiomyopathy and atrial fibrillation. Because of the high risk of thromboembolism, lifelong anticoagulation with warfarin is recommended to prevent thromboembolism in patients with atrial fibrillation and hypertrophic cardiomyopathy. The available observational data reviewed suggest that direct oral anticoagulants may be safe and effective in this patient population. However, adequately powered randomized controlled trials are needed to confirm their efficacy and safety.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rowin E.J.
        • Hausvater A.
        • Link M.S.
        • et al.
        Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy.
        Circulation. 2017; 136: 2420-2436
        • Olivotto I.
        • Cecchi F.
        • Casey S.A.
        • Dolara A.
        • Traverse J.H.
        • Maron B.J.
        Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.
        Circulation. 2001; 104: 2517-2524
      1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
        Eur Heart J. 2014; 35: 2733-2779
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • et al.
        2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy.
        Circulation. 2011; 124: e783-e831
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        2019 AHA/ACC/HRS Focused UPDATE OF THE 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
        Circulation. 2019; 140: e125-e151
        • Hendriks T.
        • McGregor S.
        • Rakesh S.
        • Robinson J.
        • Ho K.M.
        • Baker R.
        Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism—the SWAN study.
        PLoS One. 2020; 15e0234048
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Ortiz-Cartagena I.
        • Gotay A.O.
        • Acevedo J.
        Cost effectiveness of oral anticoagulation therapy for non-valvular atrial fibrillation patients: warfarin versus the new oral anticoagulants rivaroxaban, dabigatran and apixaban.
        J Am Coll Cardiol. 2018; 71: A490
        • López-López J.A.
        • Sterne J.A.C.
        • Thom H.H.Z.
        • et al.
        Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
        BMJ. 2017; 359: j5058
        • MacIntyre C.
        • Lakdawala N.K.
        Management of atrial fibrillation in hypertrophic cardiomyopathy.
        Circulation. 2016; 133: 1901-1905
        • Guttmann O.P.
        • Rahman M.S.
        • O’Mahony C.
        • Anastasakis A.
        • Elliott P.M.
        Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
        Heart. 2014; 100: 465-472
        • Lau D.H.
        • Nattel S.
        • Kalman J.M.
        • Sanders P.
        Modifiable risk factors and atrial fibrillation.
        Circulation. 2017; 136: 583-596
        • Gami A.S.
        • Hodge D.O.
        • Herges R.M.
        • et al.
        Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation.
        J Am Coll Cardiol. 2007; 49: 565-571
        • Siontis K.C.
        • Geske J.B.
        • Ong K.
        • Nishimura R.A.
        • Ommen S.R.
        • Gersh B.J.
        Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.
        J Am Heart Assoc. 2014; 3e001002
        • Philipson D.J.
        • Rader F.
        • Siegel R.J.
        Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Published online February 6.
        Eur J Prev Cardiol. 2019; https://doi.org/10.1177/2047487319828474
        • Yakar Tuluce S.
        • Kayikcioglu M.
        • Tuluce K.
        • et al.
        Assessment of left atrial appendage function during sinus rhythm in patients with hypertrophic cardiomyopathy: transesophageal echocardiography and tissue doppler study.
        J Am Soc Echocardiogr. 2010; 23: 1207-1216
        • Tuluce K.
        • Tuluce S.Y.
        • Eren N.K.
        • et al.
        Predictors of future atrial fibrillation development in patients with hypertrophic cardiomyopathy: a prospective follow-up study.
        Echocardiography. 2016; 33: 379-385
        • Autore C.
        • Bernabò P.
        • Barillà C.S.
        • Bruzzi P.
        • Spirito P.
        The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms.
        J Am Coll Cardiol. 2005; 45: 1076-1080
        • Kubo T.
        • Kitaoka H.
        • Okawa M.
        • et al.
        Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy.
        Circ J. 2009; 73: 1599-1605
        • Eleid M.F.
        • Konecny T.
        • Orban M.
        • et al.
        High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2009; 54: 1805-1809
        • Konecny T.
        • Brady P.A.
        • Orban M.
        • et al.
        Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy.
        Am J Cardiol. 2010; 105: 1597-1602
        • Sengupta P.P.
        • Sorajja D.
        • Eleid M.F.
        • et al.
        Hypertrophic obstructive cardiomyopathy and sleep-disordered breathing: an unfavorable combination.
        Nat Clin Pract Cardiovasc Med. 2009; 6: 14-15
        • Nishimura R.A.
        • Ommen S.R.
        Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death.
        Circ Cardiovasc Interv. 2010; 3: 91-93
        • Moss T.J.
        • Zipse M.M.
        • Krantz M.J.
        • Sauer W.H.
        • Salcedo E.E.
        • Schuller J.L.
        Incidence of atrial fibrillation following alcohol septal ablation for hypertrophic cardiomyopathy.
        Ann Noninvasive Electrocardiol. 2016; 21: 443-449
      2. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy.
        Circulation. 2011; 124: e783-e831
        • Lee H.-J.
        • Kim H.-K.
        • Jung J.-H.
        • et al.
        Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation.
        Stroke. 2019; 50: 2582-2586
        • Jung H.
        • Yang P.-S.
        • Jang E.
        • et al.
        Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy.
        Chest. 2019; 155: 354-363
        • Noseworthy P.A.
        • Yao X.
        • Shah N.D.
        • Gersh B.J.
        Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation.
        J Am Coll Cardiol. 2016; 67: 3020-3021